Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

InnoCare Doses First Subject in Phase 1 Trial of Autoimmune Drug ICP-B161 in China

By Public Technologies
  • InnoCare Pharma dosed the first subject in a Phase 1 trial of ICP-B161 in China on Oct. 30, 2026.
  • The bispecific antibody targets TL1A and IL-23p19 for potential treatment of autoimmune diseases, including inflammatory bowel disease.
  • Preclinical studies showed significant reductions in colitis-related symptoms with good tolerability.
  • Its extended half-life supports less frequent dosing and subcutaneous administration.
  • No bispecific antibody targeting both TL1A and IL-23p19 has been approved worldwide.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InnoCare Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610292201PRIMZONEFULLFEED9856744) on October 30, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.